Exelixis | EXEL - Gross Profit On Sales


Exelixis reported $590.86M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 279.64M 36.37M Jun/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Amgen USD 5.87B 1.02B Mar/2026
AstraZeneca USD 12.86B 251M Jun/2026
Bayer EUR 8.17B 1.24B Mar/2026
BioMarin Pharmaceutical USD 713.42M 142.21M Jun/2026
Bristol-Myers Squibb USD 9.26B 1.19B Jun/2026
Cytokinetics USD 23.03M 3.84M Jun/2026
Eisai JPY 183.24B 29.83B Jun/2026
Eli Lilly USD 16.22B 301.7M Mar/2026
Exelixis USD 590.86M 18.68M Mar/2026
Genmab DKK 1.07B 240M Jun/2026
Glaxosmithkline GBP 5.75B 2.99B Mar/2026
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
MacroGenics USD 11.24M 19.87M Mar/2026
Merck USD 12.09B 1.24B Mar/2026
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Pfizer USD -248M 11.29B Jun/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Sanofi EUR 8.11B 343M Mar/2026
Takeda JPY 813.22B 124.39B Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026